Organogenesis files to sell up to $75 million in stock through at-the-market program
The regenerative medicine company entered an ATM sales agreement with BTIG and Citizens JMP on August 6, 2026, as shares traded near $2.37.
SEC filing
Latest
3 stories
Thursday, August 6
Organogenesis cuts 2026 revenue outlook after steep quarterly sales decline
Second-quarter revenue fell 58% amid a slower-than-expected market recovery, prompting a lower full-year guidance range and continued cash burn.
SEC filing
Organogenesis enters at-the-market equity sales agreement worth up to $75 million
The company can now sell Class A common stock through BTIG and Citizens JMP Securities from time to time under a new shelf-based ATM program.
SEC filing